Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

SELLAS Stock Triples on Cancer Vaccine Cutting Death Risk by 41% in Pivotal Leukemia Trial,

SELLAS Life Sciences Group Inc. (NASDAQ:SLS) skyrocketed to a 52-week high on Tuesday with a session volume of a massive 57.567 million compared to an average volume of 6.897 million, according to Benzinga Pro data . The company released positive topline results from its pivotal randomized Phase 3 REGAL trial evaluating galinpepimut-S (GPS), an immunotherapeutic cancer vaccine for acute myeloid…

SELLAS Stock Triples on Cancer Vaccine Cutting Death Risk by 41% in Pivotal Leukemia Trial,

SELLAS Life Sciences Group Inc. (NASDAQ:SLS) shares surged to a 52-week high as positive results from a pivotal Phase 3 leukemia trial were announced. The company confirmed that its cancer vaccine, galinpepimut-S (GPS), met its primary endpoint of overall survival in the trial. GPS reduced the risk of death by 41% compared to the best available treatment.

The late-stage biopharmaceutical company licensed GPS from Memorial Sloan Kettering Cancer Center as an off-the-shelf vaccine targeting a protein expressed across multiple blood cancers and solid tumors. SLS stock is now trading at a new 52-week high of $21.14.

Written by urgent.news from Benzinga's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at benzinga.com →

More in Finance & Markets

More from Tuesday 17 November →